Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Muscular Dystrophy
 More »

  • GSK-Prosensa DMD Candidate Drisapersen Flops in Phase III Trial
    GlaxoSmithKline (GSK) and Prosensa said today their investigational drug drisapersen for Duchenne muscular dystrophy (DMD) failed to meet its primary endpoint in a Phase III ...
    9-20-2013
  • Biogen Idec and Isis Ink Fourth Deal in Two Years
    Isis' antisense drug candidate developed with Isis for Spinal Muscular Atrophy (SMA). ... a new antisense drug for myotonic dystrophy type 1 (DM1) or Steinert disease. ...
    9-9-2013
  • Repligen Earns $1M Pfizer Milestone Payment
    was the first drug discovery program ever conducted specifically for SMA. The Muscular Dystrophy Association awarded Repligen a $1.4 million grant supporting the company's ...
    9-4-2013
  • Evotec and Jain Extend Research Collab in Skeletal Muscular Dystrophy
    step toward accomplishing our mission of finding a therapy for Limb-girdle muscular dystrophy type 2B/Miyoshi myopathy (LGMD2B/MM)," said Plavi Mittal, Ph.D., Jain's ...
    8-21-2013
  • Heading, Literally, into the Future
    He maintains that such a procedure would be beneficial-in reality, life saving-for individuals suffering from muscular dystrophy, tetraplegics who are often prone to multi-organ ...
    7-10-2013
  • Large-Scale Small Molecule Screen IDs Muscular Dystrophy Target
    small molecules, scientists have identified a way to 'turn off' the defect behind myotonic dystrophy type 1. Large-Scale Small Molecule Screen IDs Muscular Dystrophy Target
    6-27-2013
  • Gene Editing to Treat Genetic Diseases, Part II
    This second part of a two-part article on treating Duchenne muscular dystrophy discusses TALENs and TAL effectors as possible treatments. Duchenne muscular dystrophy (DMD) and its ...
    6-20-2013
  • NCATS Awards $12.7M for Nine Drug Repurposing Projects
    ... Krieger Institute, and Stanley C. Froehner, Ph.D., of the University of Washington for investigations on an undisclosed Sanofi compound against Duchenne muscular dystrophy (DMD). ...
    6-18-2013
  • Gene Editing with Multiple Molecular Means
    This first part of a two-part article on treating Duchenne muscular dystrophy focuses on a potential new treatment that interferes with nonsense mutations. Using genetic editing, ...
    6-12-2013
  • MDA Gives Valerion's Preclinical MTM Pipeline $1.2M Boost
    The Muscular Dystrophy Association (MDA)'s Venture Philanthropy arm has injected $1.2 million into Valerion Therapeutics' myotubular myopathy (MTM) pipeline, funding the firm to ...
    5-31-2013
  • Top 20 Grant-Giving Disease Foundations
    ... $3.500 million % Awarded as Grants: 89.6% Headquarters: Washington, DC #8. Muscular Dystrophy Association % of Revenues Awarded as Grants: 21.7% 2011 Total Unrestricted ...
    5-21-2013
  • ARMGO Gets $1M for Muscular Dystrophy Drug
    ARMGO Pharma received a $1 million award from the Muscular Dystrophy Association (MDA) for preclinical work in support of an investigational new drug application with the FDA for ...
    4-17-2013
  • Stem Cell Lines
    cancer, Wilm's tumor, and Von Hippel-Lindau syndrome), Huntington's disease, muscular dystrophy (including CMT, FSHD, and Myotonic), and cystic fibrosis as well as some rarer ...
    3-15-2013
  • Parkinson's Collaboration Hopes to Spark New Therapy
    as one million Americans live with the disease, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease. ...
    2-27-2013
  • Repligen, Pfizer Make $70M Spinal Muscular Atrophy Deal
    SMA. Repligen's research and clinical efforts, including the current Phase Ib trial, have been partially supported by a $1.4 million grant from the Muscular Dystrophy Association. ...
    1-3-2013
  • More »

    Journal Articles

  • Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy
    Helen Foster, Linda Popplewell, George Dickson
    Human Gene Therapy and Part B: Methods
    Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy Human Gene Therapy and Part B: Methods Abstract Despite an expansive wealth of research following the discovery of ...
  • Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne...
    Norma B. Romero, Serge Braun, Olivier Benveniste, France Leturcq, Jean-Yves Hogrel, Glenn E. Morris, Annie Barois, Bruno Eymard, Christine Payan, Véronique Ortega, Anne-Laure Boch, Lise Lejean, Christine Thioudellet, Brigitte Mourot, Christophe Escot, Aurore Choquel, Dominique Recan, Jean-Claude Kaplan, George Dickson, David Klatzmann, Valérie Molinier-Frenckel, Jean-Gérard Guillet, Patrick Squiban, Serge Herson, Michel Fardeau
    Human Gene Therapy and Part B: Methods
    Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy Human Gene Therapy and Part B: Methods Nine patients with Duchenne or Becker muscular ...
  • Clinical Trials Using Antisense Oligonucleotides in Duchenne...
    Taeyoung Koo, Matthew J. Wood
    Human Gene Therapy and Part B: Methods
    Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy Human Gene Therapy and Part B: Methods Duchenne muscular dystrophy (DMD) is a severe muscle wasting ...
  • Cell and Gene Therapy in Duchenne Muscular Dystrophy
    Jennifer Elizabeth Morgan
    Human Gene Therapy and Part B: Methods
    Cell and Gene Therapy in Duchenne Muscular Dystrophy Human Gene Therapy and Part B: Methods

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll